Boehringer Ingelheim

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. 

News from this company

News

Boehringer Ingelheim Announces Leadership Changes in Shareholders’ Committee and Board

17.04.2025 -

The Shareholders’ Committee of Boehringer Ingelheim have announced the following appointments in the Shareholders’ Committee and the Board of Managing Directors...

News

Boehringer Ingelheim Opens New R&D Center in Basel

07.04.2025 -

NBE Therapeutics (NBE), a wholly owned subsidiary of  Boehringer Ingelheim, officially opened its new ADC R&D facility in Basel.

News

Boehringer Ingelheim Expands Cancer Research at Vienna Site

30.09.2024 -

On Sep. 25, German biopharma company Boehringer Ingelheim opened its new 11,000 sqm Angelika Amon Research Building at its site in Vienna, Austria. According to...

News

Boehringer to Expand Greek Production Site for New Medicines

19.01.2024 -

German drugmaker Boehringer Ingelheim is investing €120 million in an upgrade and expansion of its facility in Koropi, Greece, that will increase the company's capacity...

News

Boehringer Ingelheim, Evotec and BioMérieux Link on AMR

14.07.2022 -

German biopharma Boehringer Ingelheim, compatriot CDMO Evotec and French diagnostics firm BioMérieux have formed a joint venture to develop a new approach to fight the...

Contact

Boehringer Ingelheim

Binger Str. 173
55218 Ingelheim

+49 6132 77 0
+49 6132 77 3000